Bayer 17833: A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL) - CHRONOS-4

September 17, 2018
https://clinicaltrials.gov/ct2/show/NCT02626455
Cancer - Lymphoma
Principal Investigator: Philip Kuriakose, MD
Lymphoma, Non-Hodgkin's, CHRONOS-4
Accepting Participants